Holen Sie sich die Stockscreener-App
10.04
3.18%
-0.33
Schlusskurs vom Vortag:
$10.37
Offen:
$10.37
24-Stunden-Volumen:
173.72K
Relative Volume:
0.53
Marktkapitalisierung:
$571.92M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-67.45M
KGV:
-8.459
EPS:
-1.1869
Netto-Cashflow:
$-52.41M
1W Leistung:
-5.99%
1M Leistung:
+0.90%
6M Leistung:
+55.66%
1J Leistung:
+103.44%
1-Tages-Spanne:
$9.87
$10.37
1-Wochen-Bereich:
$9.86
$10.72
52-Wochen-Spanne:
$2.60
$11.14
Design Therapeutics Inc Stock (DSGN) Company Profile
Firmenname
Design Therapeutics Inc
Sektor
Branche
Telefon
858-293-4900
Adresse
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
10.04 | 590.71M | 0 | -67.45M | -52.41M | -1.1869 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.36 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
724.67 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.19 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.66 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-03 | Eingeleitet | Craig Hallum | Buy |
| 2025-12-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-05-04 | Hochstufung | Goldman | Sell → Neutral |
| 2022-06-10 | Eingeleitet | Wedbush | Outperform |
| 2022-05-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-19 | Eingeleitet | Goldman | Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-20 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
Edgewise Therapeutics, Inc. (EWTX) Stock Price, News, Quote & History - Yahoo Finance
Earnings Risk: Will Design Therapeutics Inc benefit from green energy policies2025 Big Picture & Daily Entry Point Trade Alerts - baoquankhu1.vn
Design Therapeutics (DSGN) Expected to Announce Quarterly Earnings on Monday - Defense World
DSGNDesign Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
DSGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Fuchs Dystrophy Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, Santen - Barchart.com
Stock List: Research Stocks from Around the World - GuruFocus
Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer Conference - MarketBeat
DSGN: Clinical-stage genetic medicine programs in FA, FECD, and DM1 advance toward key data readouts - TradingView
Design Therapeutics (NASDAQ:DSGN) Hits New 1-Year HighWhat's Next? - MarketBeat
LEVI & KORSINSKY, LLP INVESTIGATING ALLEGED CLINICAL TRIAL DESIGN DEFICIENCIES AT VISTAGEN THERAPEUTICS -- CLASS ACTION FILED - PR Newswire
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026 - The Manila Times
K36 Therapeutics Highlights First-in-Human KTX-2001 Prostate Cancer Study Design at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2026 - PR Newswire
DSGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials - Business Wire
Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00 - Defense World
Ideas Watch: Can Design Therapeutics Inc expand its profit margins2025 Trading Recap & Capital Protection Trade Alerts - baoquankhu1.vn
Design Therapeutics (NASDAQ:DSGN) Sees Strong Trading VolumeShould You Buy? - MarketBeat
RSI Check: Is Trinseo PLC a potential multi baggerBond Market & Breakout Confirmation Alerts - baoquankhu1.vn
Design Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference - Bitget
Biotech Design Therapeutics to brief investors at two healthcare events - Stock Titan
Short Interest in Design Therapeutics, Inc. (NASDAQ:DSGN) Drops By 14.0% - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Will Design Therapeutics Inc. stock recover after earningsJuly 2025 Sentiment & Fast Exit and Entry Trade Guides - mfd.ru
Design Therapeutics (NASDAQ:DSGN) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Is Design Therapeutics Inc. stock influenced by commodity pricesJuly 2025 Earnings & Verified Chart Pattern Signals - mfd.ru
Trading Action: What is the long term forecast for Design Therapeutics Inc stockDip Buying & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Retail Surge: Is Design Therapeutics Inc attractive for institutional investorsJuly 2025 Catalysts & Expert-Curated Trade Recommendations - baoquankhu1.vn
Galux Raises $29M Series B to Advance AI-Driven Protein Design for Drug Discovery - Business Wire
Design Therapeutics Approaches Key Clinical Milestones with Ample Funding - AD HOC NEWS
Published on: 2026-02-07 15:17:14 - baoquankhu1.vn
Is Design Therapeutics Inc. stock near bottom after decline2025 Market WrapUp & AI Powered Buy/Sell Recommendations - mfd.ru
Generate Biomedicines, Clinical-Stage Generative Biology Company Designing AI-Engineered Protein Therapeutics, Files for Nasdaq IPO - TradingView
Design Therapeutics (NASDAQ:DSGN) Shares Gap Up – Here’s Why - Defense World
Published on: 2026-02-01 06:18:16 - baoquankhu1.vn
Design Therapeutics announces governance-driven board resignation - The Globe and Mail
How volatile is Design Therapeutics Inc. stock2025 Support & Resistance & Momentum Based Trading Ideas - mfd.ru
Loss Report: How volatile is Design Therapeutics Inc stockEarnings Summary Report & Fast Moving Market Watchlists - baoquankhu1.vn
Design Therapeutics, Inc. Announces Resignation of Deepa Prasad from the Company's Board of Directors, Effective February 1, 2026 - marketscreener.com
Design Therapeutics (NASDAQ:DSGN) Shares Gap UpStill a Buy? - MarketBeat
Recap Report: Does Design Therapeutics Inc meet Warren Buffetts criteria2025 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Insider Sell: Can Design Therapeutics Inc expand its profit marginsBond Market & AI Enhanced Trading Alerts - baoquankhu1.vn
Design Therapeutics (NASDAQ:DSGN) Reaches New 1-Year HighHere's What Happened - MarketBeat
Bear Alert: Is Design Therapeutics Inc attractive for institutional investorsTrade Performance Summary & Reliable Price Breakout Signals - baoquankhu1.vn
Eclipsebio Acquires Terrain Bio to Expand Its End-to-End AI Platform for the Design, Manufacturing, and Validation of RNA Therapeutics - BioSpace
Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics - Business Wire
MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics - Yahoo Finance
Design Therapeutics (NASDAQ:DSGN) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Trading Recap: Will Bullfrog AI Holdings Inc Equity Warrant stock recover after earningsQuarterly Profit Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Finanzdaten der Design Therapeutics Inc-Aktie (DSGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):